四环医药：轩悦宁 (吡洛西利片)第三个适应症上市申请获得NMPA批准用于一线治疗HR+/HER2-晚期乳腺癌

Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing) as a first-line treatment for HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Group 1: Company Developments - Four Ring Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer [1]. - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and subsequent lines [1]. Group 2: Market Context - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer accounts for approximately 75% of cases in China, with about 30% of these patients diagnosed at an advanced stage [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer in China is expected to reach RMB 13 billion by 2032 [2]. Group 3: Clinical Research Insights - The approval for the new indication is based on data from the BRIGHT-3 study, a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The BRIGHT-3 study results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months [3]. - Pyrotinib demonstrated a 47% reduction in the risk of disease progression or death compared to the control, with a notable 64% reduction in patients with liver metastases [3]. - The overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were manageable and primarily of grade 1-2 severity, indicating an overall controllable safety profile [3].